.jpg "Analysts Offer Insights on Healthcare Companies: Sophiris Bio (NASDAQ: SPHS) and Mersana Therapeutics Inc (NASDAQ: MRSN)")
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sophiris Bio (NASDAQ: SPHS) and Mersana Therapeutics Inc (NASDAQ: MRSN) with bullish sentiments.
Sophiris Bio (NASDAQ: SPHS)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Sophiris Bio (NASDAQ: SPHS), with a price target of $6. The company’s shares closed yesterday at $3.09, close to its 52-week high of $3.14.
According to TipRanks.com, Pantginis is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -11.3% and a 38.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Currently, the analyst consensus on Sophiris Bio is Moderate Buy and the average price target is $7, representing a 126.5% upside.
In a report released today, Maxim Group also maintained a Buy rating on the stock with a $8 price target.
See today’s analyst top recommended stocks >>
Mersana Therapeutics Inc (NASDAQ: MRSN)
In a report released today, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on Mersana Therapeutics Inc (NASDAQ: MRSN), with a price target of $33. The company’s shares closed yesterday at $16.51.
According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 2.9% and a 50.0% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Jounce Therapeutics Inc, and Audentes Therapeutics.
Currently, the analyst consensus on Mersana Therapeutics Inc is Strong Buy and the average price target is $27.33, representing a 65.5% upside.
In a report issued on May 8, Robert W. Baird also initiated coverage with a Buy rating on the stock with a $30 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
